Asia-Pacific Pharmacogenetic Testing in Psychiatry/Depression Market – Industry Trends and Forecast to 2028

  • Medical Devices
  • Published Report
  • Mar 2021
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 115
  • No of Figures: 47

Asia-Pacific Pharmacogenetic Testing in Psychiatry/Depression Market, By Type (Whole Genome Sequencing and Array-Based Tests), Genes (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and Others), Drug Type (Prescription Drugs, Over-the-Counter Medications, Recreational Drugs and Vitamins/Nutraceuticals), Sample Type (Saliva and Blood), Application (Drug Development and Clinical Practice), End User (Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, Healthcare Providers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Direct-to-Consumer Services and Mail-Order Pharmacies), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2028

Asia-Pacific Pharmacogenetic Testing in Psychiatry/Depression MarketMarket Analysis and Insights: Asia-Pacific Pharmacogenetic Testing in Psychiatry/Depression Market

The pharmacogenetic testing in psychiatry/depression market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 10.6% in the forecast period of 2021 to 2028 and is expected to reach USD 276.10 million by 2028 from USD 124.87 million in 2020. Growing prevalence of cancer disease, novel technology in pharmacogenetics testing for treatment of depression and pharmacogenomics testing are the major drivers which propelled the demand of the pharmacogenetic testing in psychiatry/depression market in the forecast period.

Pharmacogenetic test is a drug gene test which is used to determine the interaction between the drug and the genetic make-up of the individual. These tests aid the medical professionals to choose the best medicine for the person who is undertaking the drug because it is observed that different people react differently to drugs based on the expression of genes induced by the drugs.

With the rising prevalence of depression, the demand of pharmacogenetics testing is also increasing as it studies the effect of genetic variants with the aim of furnishing tailored treatment and the pharmacogenetic testing in psychiatry/depression market is expected to grow in coming years. The lack of basis to entirely depend on the tests is a major drawback in the pharmacogenetic testing in psychiatry/depression market. The patients would prefer to stick to traditional methods of testing and thus it will restrict the pharmacogenetic testing in psychiatry/depression market growth. The tests also help to establish a meaningful relationship between a drug and the genetic makeup of the individual. This helps in deciding the drugs to be administered to the patient to treat major depressive disorders and other psychiatric conditions acting as an opportunity for the pharmacogenetic testing in psychiatry/depression market growth. The stringent government regulation on new products and instruments approval will likely to challenge the pharmacogenetic testing in psychiatry/depression market growth.

The pharmacogenetic testing in psychiatry/depression market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the pharmacogenetic testing in psychiatry/depression market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Pharmacogenetic Testing in Psychiatry/Depression MarketPharmacogenetic Testing in Psychiatry/Depression Market Scope and Market Size

The pharmacogenetic testing in psychiatry/depression market is categorized into seven notable segments which are based on the type, genes, drug type, sample, application, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the pharmacogenetic testing in psychiatry/depression market is segmented into whole genome sequencing and array-based tests. In 2021, whole genome sequencing segment is expected to dominate the market due to high technological adoption by key players in the market.
  • On the basis of genes, the pharmacogenetic testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and others. In 2021, CYP2C19 segment is expected to dominate the market due to increasing influence of genes on medications.
  • On the basis of drug type, the pharmacogenetic testing in psychiatry/depression market is segmented into prescription drugs, over-the-counter medications, recreational drugs and vitamins/nutraceuticals. In 2021, prescription drugs segment is expected to dominate the market due to increasing demand of personalized medicines.
  • On the basis of sample, the pharmacogenetic testing in psychiatry/depression market is segmented into saliva and blood. In 2021, saliva segment is expected to dominate the market because of advanced technologies present in the market.
  • On the basis of application, the pharmacogenetic testing in psychiatry/depression market is segmented into drug development and clinical practice. In 2021, drug development segment is expected to dominate the market because of rising demand of precision diagnosis.
  • On the basis of end user, the pharmacogenetic testing in psychiatry/depression market is segmented into pharmaceutical & biotechnology companies, research centers and academic institutes, healthcare providers and others. In 2021, pharmaceutical & biotechnology companies segment is expected to dominate the market because of large number of players present in the market.
  • On the basis of distribution channel, the pharmacogenetic testing in psychiatry/depression market is segmented into hospital pharmacies, retail pharmacies, direct-to-consumer services and mail-order pharmacies. In 2021, hospital pharmacies segment is expected to dominate the market because of increasing demand of customized and precision diagnosis.

Pharmacogenetic Testing in Psychiatry/Depression Market Country Level Analysis

The pharmacogenetic testing in psychiatry/depression market is analysed and market size information is provided by the country, type, genes, drug type, sample, application, end user and distribution channel as referenced above.

The countries covered in the pharmacogenetic testing in psychiatry/depression market report are Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and rest of Asia-Pacific.

Asia-Pacific is expected to grow with the highest CAGR in the forecast period in the region due to the demand for precision medicine is increasing very rapidly. Japan is expected to dominate in the Asia-Pacific pharmacogenetic testing in psychiatry/depression market. Japan is one of the leading countries in the world with rapidly increasing diagnosis rate with rising government initiatives for awareness regarding importance of diagnosis and treatment for major depressive disorders.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Strategic Collaboration and Product Launch by Manufactures is Creating New Opportunities for Players in the Pharmacogenetic Testing in Psychiatry/Depression Market

The pharmacogenetic testing in psychiatry/depression market also provides you with detailed market analysis for every country growth in aesthetic industry with pharmacogenetic testing in psychiatry/depression sales, impact of advancement in the pharmacogenetic testing in psychiatry/depression and changes in regulatory scenarios with their support for the pharmacogenetic testing in psychiatry/depression market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Pharmacogenetic Testing In Psychiatry/Depression Market Share Analysis

The pharmacogenetic testing in psychiatry/depression market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to pharmacogenetic testing in psychiatry/depression market.

The major players covered in the pharmacogenetic testing in psychiatry/depression market are BiogeniQ Inc., GenXys, Genomind, Inc., Myriad Genetics, Inc., AltheaDx, STADA Arzneimittel AG, Sonic Healthcare, ONEOME, Thermo Fisher Scientific Inc., Millennium Health, Coriell Life Sciences, Healthspek, Color, GENELEX, OmeCare, AB-Biotics, S.A., F. Hoffmann-La Roche Ltd, Luminex Corporation, Illumina, Inc., PerkinElmer Inc., HudsonAlpha Health Alliance (a division of HudsonAlpha), Dynamic DNA Laboratories, cnsdose, myDNA Life Australia Pty Ltd., R-Biopharm AG among other domestic and Asia-Pacific players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which also accelerating the pharmacogenetic are testing in psychiatry/depression market.

For instance,

  • In July 2020, Myriad Genetics, Inc. announced the launch of a home collection kit for patients for the GeneSight Psychotropic Test. The test will help the doctors understand the impact of antidepressants and other drugs related to the same on the genetic makeup of the patient. This will help them administer drugs that will be suitable for their patients improving the outcomes. This will help in the growth of the market in fore coming years.
  • In August 2018, Dynamic DNA Laboratories launched PGx testing for depression medication, which is the most personalized approach to prescribing medication. This product helps to understand that which medication best suits a person suffering from depression and also allow to experience less side effects. This launch boosted the company’s product portfolio and allowed it to expand its root in pharmacogenetics testing in psychiatry/depression market.

Collaboration, joint ventures and other strategies by the market players is enhancing the company market in the pharmacogenetic testing in psychiatry/depression market which also provides the benefit for organisation to improve their offering for pharmacogenetic testing in psychiatry/depression.

Customization Available: Asia-Pacific Pharmacogenetic Testing in Psychiatry/Depression Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD MILLION)

TABLE 2 ASIA-PACIFIC WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 3 ASIA-PACIFIC ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD MILLION)

TABLE 5 ASIA-PACIFIC CYP2C19 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 ASIA-PACIFIC CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC CYP2D6 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC HLA-B IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC HTR2A/C IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC HLA-A IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC CYP3A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC SLC6A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC MTHFR IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC COMT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD MILLION)

TABLE 17 ASIA-PACIFIC PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC VITAMINS/NUTRACEUTICALS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD MILLION)

TABLE 22 ASIA-PACIFIC SALIVA IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC BLOOD IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD MILLION)

TABLE 25 ASIA-PACIFIC DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC CLINICAL PRACTICE IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD MILLION)

TABLE 28 ASIA-PACIFIC PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 ASIA-PACIFIC HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD MILLION)

TABLE 33 ASIA-PACIFIC RETAIL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC HOSPITAL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION))

TABLE 36 ASIA-PACIFIC DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 43 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 44 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 45 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 46 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 47 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 48 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 49 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 50 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 51 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 52 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 53 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 54 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 55 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 56 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 57 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 58 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 59 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 60 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 61 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 62 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 63 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 64 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 65 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 66 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 67 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 68 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 69 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 70 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 71 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 72 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 73 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 74 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 75 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 76 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 77 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 78 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 79 AUSTRALIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 80 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 81 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 82 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 83 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 84 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 85 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 86 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 87 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 88 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 89 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 90 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 91 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 92 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 93 THAILAND PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 94 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 95 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 96 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 97 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 98 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 99 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 100 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 101 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 102 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 103 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 104 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 105 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 106 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 107 INDONESIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 108 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

TABLE 109 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE, 2021-2028 (USD MILLION)

TABLE 110 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)

TABLE 111 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, 2021-2028 (USD MILLION)

TABLE 112 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)

TABLE 113 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)

TABLE 114 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

TABLE 115 REST OF ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions